Cassava shares are down 34c, or 12%, to $2.46 in pre-market trading after resuming following a halt for news pending.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SAVA:
- Cassava Sciences’ Alzheimer’s Drug Trials Fall Short, Neutral Rating Maintained Amid Uncertainties
- Cassava Sciences Amends Bonus Plan After Court Settlement
- H.C. Wainwright focused on what results from Cassava’s ReFocus-ALZ might reveal
- Cassava Sciences Reports 2024 Financial Results and Strategic Updates
- Cassava Sciences reports Q4 EPS (57c) vs (50c) last year